Skip to content

Adaptive Biotechnologies ADPT Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$20.02M-47.4%-$13.58M-242%$9.55M+137%-$25.59M+14.2%-$29.83M+11.5%
$3.42M-9.2%$3.77M-5.3%$3.98M-2.5%$4.08M-5.4%$4.31M+7.3%
$11.93M-6.2%$12.72M-4.1%$13.26M-0.8%$13.36M+10.0%$12.15M-5.3%
-$9.54M$0+100%-$7.13M+42.7%-$12.43M+56.4%-$28.48M-128%
$796K+25.2%$636K+55.5%$409K-37.6%$655K-48.0%$1.26M+1,474%
$9.14M$17.28M+417%$3.35M-86.9%$25.57M+15.6%
$7.5M-65.4%$21.66M+1,186%$1.68M+4.6%$1.61M-70.5%$5.45M+4,192%
$7.11M-54.0%$15.46M+30.6%$11.84M+258%-$7.47M-394%$2.54M
-$10.33M$0+100%-$7.54M+42.4%-$13.09M+56.0%-$29.74M-137%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Adaptive Biotechnologies generate?
Adaptive Biotechnologies (ADPT) generated -$29.1M in operating cash flow over the trailing twelve months.
What is Adaptive Biotechnologies's free cash flow?
After $2.5M of capital expenditures, Adaptive Biotechnologies's free cash flow was -$31.0M over the trailing twelve months, up 65.1% year over year.
Where does Adaptive Biotechnologies's cash flow data come from?
Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.